text:
There are so many speed demons on the road every day in Louisiana. They drive me off the highway, cut me off in traffic and the only thing one can think of is, "whoa did you see that awesome 2009 MX5 Miata?" Yes, there are some of us that have a thing for sports cars and a need for speed. Unfortunately, insurance companies have a need to dig deeper into our pockets too. Can you really say Sports Car and Insurance deal in the same sentence?
Believe it or not there are auto insurance deals for sports cars out there, you just have to know how to look. First you want to get your fingers ready to shop around on the Internet. The good thing is you only have to fill out the form once. The bad thing is the form takes about 45 minutes asking you everything about your previous driving history. If you already have a Sports car than you should really consider a top-notch anti-theft-prevention system for your car assuming that you don't already have one. You might want to get the alarm system that is the best money can buy. You know, the one that is so expensive it comes with a police officer that follows your car everywhere it goes. You insurance company will acknowledge your theft prevention system and give you some kudos: that is money off your premium. Not to mention those new anti-lock brakes that you just had installed along with the stability and traction controls.
Secondly, keep your credit rating up if anything to just go against the norm and be different. It is bad enough that you have a sports car but you have bad credit too? Take care of any credit card debt before you apply for a car insurance policy. Insurance companies will offer you better insurance premiums to the drivers with better scores.
If your going to call yourself a performance driver than it might be in your best interest if you keep performing well on your driving record. Another way to keep your premium low on your sports car is to research before buying your car insurance. Insurance companies offer different rates. Usually, when a companies sales are up they tend to take back some of the deals they had going on a year ago. When the sales go down they will do anything they can to get your business.
As a sports car owner it would be smart if you keep yourself informed and search on the Internet about the discounts and rates for your type of vehicles insurance. Always look for any special events or discount offers when searching for auto insurance deals for sports cars. Having a sports car should be fun and insurance should not take that away from the drivers. Research your options and know that there are great auto insurance deals for sports cars out there all you just have to look.


text:
i know - i use it as docker app in unraid - but it is basically the 5420 version. beside the before mentioned visual prob with the queue list in webplayer, there are several probs - like adding new user - database errors, and some minor typo's in help baloons. i know, it's a beta. i am not complaining - it is working, the good outweights the bad. but, it still needs some attention.
maybe some other ppl could chime in here as well.
cheers, L
btw, i will try to get to the typo's again soon (like after the holidays) for details where i noticed it for changes in the future. as far as the noticed db errors go - i can replicate them and happy to send them, otherwise i will be no help there - just not having the knowledge what the real prob is. the covered up queue list should be a simple issue - it wasn't there in the last version i used.
cheers, L
Post your Server Bug Report
Post Reply
First unread post • 1 post • Page 1 of 1
Post Reply
1 post • Page 1 of 1

subset: commoncrawl


text:
Having trouble finding a gift for your best friend? Or perhaps you want to drop a few hints to your boyfriend or hubby?
Here are some nifty gift ideas:
1. Clinique Personalized 'Happy' Perfume, allows you to place your own picture on the bottle! $52
2. Prescriptives Colorscope Refillable Eye and Cheek Palette (Warm & Cool), $52
3. Lancome Jeweled Affair Palette, $52.50
4. Sephora So Belle Multi-use Palette, $25
5. Sephora Metallic Sequin Clutch, $18
6. Philosophy Multi-Use wash in Cinnamon Buns, $16
7. Napolean Perdis Palette, $39
8. POP Beauty Lid Silver, smoldering silver smokey looks! $22
9. Sephora Electro-Glitter Eye Pencils, $8 (awesome dupe of MAC glitter eye pencils)
10. LORAC Mini Mocktal Bar Lipgloss Set, $25
11. Sugar I dream of sugar palette, $38
12. Laure Geller Baked Basics (dupe of MAC MSF's), $48
13. Sephora Glitter Spray, $8
Recent Posts
Popular Posts
Upcoming Posts
Friday, November 30, 2007
Holiday Gift Ideas and Stocking Stuffers
Having trouble finding a gift for your best friend? Or perhaps you want to drop a few hints to your boyfriend or hubby?
5 comments
- Lani said...
Hey Vanessa! Never had a chance to drop some makeup love so here I am! I read your blog almost everyday. You and Stephie, actually. I like how you update often. I would like to but I wish there were 48 hours in a day lol. BTW, I bought that napoleon perdis palette and i love it! i agree, it would make a great gift! well i will be around as usual. take care and happy holisdays!
- December 1, 2007 at 11:41 AM
- Chiara said...
Nessa! What are you getting your boy for Christmas??
-itsizzy from ABB
- December 1, 2007 at 1:53 PM
- Anonymous said...
I love those Sephora glitter pencils. They sound awesome. I have some stuff to exchange at Sephora worth a lot of $$ so I'm probably going to pick up one or two of those!
Also, anything Philosophy is great. I have the 3-in-1 Philsophy of Sweet Coconut Milk (16$) and it smells lovely!
- December 1, 2007 at 2:47 PM
- Stephie said...
hi ate :) great ideas! do you know what the philosophy stuff could be used for? <3 you!
- December 1, 2007 at 7:10 PM
- Unknown said...
Hi! It's almost mother's day and your blog just gave me an idea what to get my mom! I think she'll like the Sephora Glitter Spray. Thanks for the tips! But first I have got to make extra money *winks* thanks again!
- April 25, 2010 at 7:24 PM


text:
Previous Chapter | Table of Contents | Next Chapter
Don't Rush, Ming'er Will Be Here Soon
The one to help her make a decision finally arrived.
Feng Yu Heng subconsciously let out a sigh of relief. That sharp wind rushed to her side. A hand reached over and grabbed hold of the whip in her hand. Very quickly, a man that was refined like a deity appeared in front of her. Without making a sound, his mouth moved to tell her: "Leave him an inch from death. Give yourself some wiggle room. Don't rush, Ming'er will be here soon."
She obediently loosened her grip slightly and hesitantly chose to spare Xuan Tian Ye's worthless life.
Feng Jin Yuan let out a long sigh of relief. Just as he was about to step forward to help Xuan Tian Ye back, Kang Yi pulled him back at this critical moment, quietly saying: "Don't go. You are not in a position to do this."
Feng Jin Yuan was startled and finally remembered that he was indeed not in any position to do anything. The person that had beaten Xuan Tian Ye was Feng Yu Heng. His relationship with this second daughter was already very frayed. If he went to help the third prince at this time, perhaps Feng Yu Heng would view him as an enemy.
In fact, he did not know that even without helping Xuan Tian Ye, Feng Yu Heng already viewed him as an enemy.
Feng Yu Heng let go of the whip in her hand. Xuan Tian Hua, who had arrived in a timely manner, let out a sigh of relief but did not dare let go of her hand because he could feel the girl's hands still trembling. He knew that Feng Yu Heng did everything that she could to protect her mother and younger brother from being harmed; however, after Feng Zi Rui was targetted for assassination, Yao shi also met with a crisis.
"Don't worry." He gently said: "When Ming'er returns, he will definitely give a fair judgment." He then turned his head and looked to the servants of the Xiang Palace, "Quickly bring your prince back into the palace!"
Some servants immediately came forward and helped Xuan Tian Ye, but they simply did not know how to act. Feng Yu Heng's whip had only loosened; however, it had not been removed from Xuan Tian Ye's body. Moreover, even if it had been removed, this person was cut up and had countless broken bones. How should they support him?
"Heng Heng." Xuan Tian Hua grabbed her hand and slightly advised her: "Be obedient and let go."
She let go, and the whip fell into Xuan Tian Hua's hand.
Xuan Tian Hua flicked his wrist, and the whip that was wrapped around Xuan Tian Ye immediately came off his body. It had a similar feeling to a sword being stabbed into someone's body then suddenly being pulled out. Not only did it come with blood, it also came with chunks of flesh.
No longer under the control of the whip, there was no way for Xuan Tian Ye to remain upright, as he dropped blankly to the ground. The servants quickly went to catch him, but when they caught his tattered body, the pain caused Xuan Tian Ye to let out a cry.
He had always been a tough person. When Feng Yu Heng's whip had stabbed into his shoulder, he did not make a sound; however, he could not help but scream out in pain now.
Xuan Tian Ye was extremely confused. Normally, with such severe injuries and such extremely blood loss, a person should have fainted. But he only felt pain and discomfort; however, he did not lose consciousness. Previously, he felt for an instant that he would die, but after that, for some reason, he woke up once more.
This feeling of suffering was truly too great!
Of course, Xuan Tian Ye did not know that in the instant Feng Yu Heng had let go of the whip, she had taken out a needle and stabbed it into him. That needle had been soaked in a cardiac stimulant. Once it reached his chest, how could he possibly faint so easily?
"Your Highness the third prince." She spoke while stepping forward. She could no longer be bothered with referring to him as third brother. "Today, seventh brother spoke of pardoning you, so I will allow you to live, but the things that you have done, I have remembered them all in my heart. You absolutely should not consider yourself lucky. You absolutely should not believe that just this once is enough for me. A-Heng may not be capable when it comes to other things, but my memory is good, and I am extremely petty. Anyone that has offended me will be kept track of in a notebook. Anyone that has troubled me once, I will trouble them ten times over without sparing any expense!" After she finished speaking, she reached out and quickly pulled the needle from Xuan Tian Ye's body.
There was not a single place on Xuan Tian Ye's body that did not hurt. He could not feel the needle being pulled out at all; however, he had been quite shocked by the powerful resentment in Feng Yu Heng's words.
He opened his mouth and tried his best to say: "Father Emperor will not forgive you!"
Feng Yu Heng nodded, "Don't worry. I also will not forgive you." After saying this, she stood up and said to the servants of the Xiang Palace: "Quickly carry him in. If you don't do it quickly, this county princess will begin to feel regret."
Upon hearing this, the servants of the Xiang Palace picked him up. Their movements had been too large, as they heard Xuan Tian Ye let out a scream. The sound was even more saddening than the cries of slaughtered pigs.
Feng Jin Yuan wiped away some sweat from his brow. His legs trembling, he sighed and said: "Not bad, at least he was left with his life."
Kang Yi said: "That's right! Otherwise, beating a prince to death, I fear the punishment for such a crime is nine familial executions."
The calm that Feng Jin Yuan had just found was immediately lost once more. Nine familial executions, how could he have forgotten about this?
He did not know if Kang Yi was deliberately scaring him, but just as he was regretting nearly being implicated, Kang Yi added: "His life was saved, but with such grave injuries, with the exception of county princess herself, are there any doctors in this world that can cure him?"
Cheng Jun Man heard this from the side and interjected: "Da Shun has another divine doctor named Yao Xian. He should be able to do it."
Cheng Jun Mei, however, immediately said: "Divine doctor Yao Xian is county princess' maternal grandfather, which is to say Lady Yao's father. With his daughter being poisoned, would he saved the one who poisoned her?"
Feng Jin Yuan's heart did not just cool down. It completely froze over!
That's right, with the third prince injured to this degree, what was the point of him being left alive? Who could save him?
Kang Yi let out a long sigh and said to Feng Jin Yuan: "Husband, let's go back. Thinking about it, county princess and his Highness Prince Chun must have things to discuss. There is nothing that we can do to help here. There's no need to remain here."
Feng Jin Yuan naturally knew that Feng Yu Heng and Xuan Tian Hua would definitely have things to discuss. They would definitely have their thoughts and decisions based on this matter. He really wanted to know what sort of ideas Xuan Tian Hua would come up with for Feng Yu Heng, but when he looked at the two, they did not even look in the Feng family's direction. What face did he have to remain?
"Forget it." He waved his hand, "Let's return to the manor."
After the Feng family's people returned to their manor, the servants of the Xiang Palace rushed out to quickly clean up the blood and flesh in front of the gates. Even Mei Xiang's corpse was wrapped up in a mat.
After it was tidied up, the servants saluted Xuan Tian Hua and Feng Yu Heng. Without saying another word, they quickly closed the palace's gates.
Everything had once again become peaceful.
In front of the Xiang Palace, Feng Yu Heng and Xuan Tian Hua looked at each other. Huang Quan and Qing Yu stood behind her, while Xuan Tian Hua stood alone.
He said: "Your father sent someone into the palace to report on the situation. My people heard about it and immediately reported to me. I was in a rush to come over here, so I did not ask too much about what had happened. I only heard that third brother ordered for someone to give Lady Yao spirit-altering drug, and this was found out by you."
Feng Yu Heng nodded, "The matter of him, Kang Yi and Feng Jin Yuan collaborating in the battle of the Northwest and injuring Xuan Tian Ming is something that I have kept bottled inside with no place to vent my anger. I still have not had a chance to discuss with Xuan Tian Ming what to do about him working with concubine An and the fifth prince to poison the Northwest army. Now, he actually dares to bribe one of my Feng manor's servants to harm my mother! Seventh brother, how should I endure this?"
While she spoke, the area between her brows twitched with a hard to hide grief. Xuan Tian Hua hated seeing this. Uncontrollably, he raised his hand and patted the area between her brow. He did it again and again, but he could not get it to ease up in the slightest.
He smiled bitterly, "It seems that the only one that can soothe your feelings is Ming'er. When I came over, I already sent a hidden guard over to the military camp. Counting the time, he will be here first thing tomorrow at the latest. Heng Heng, I know that you are unreconciled, but he is still a prince. Even if father Emperor is hoping that you can beat him to death, hope is one matter. Actually doing it is another. If you killed a prince, how should the people in this world look at this matter?"
Feng Yu Heng did not think of what the people of this world would think. Instead, she only heard the other part of what he had said, "Seventh brother said that the Emperor also hopes that I can beat Xuan Tian Ye to death?"
He did not say it directly, but he did say: "Father Emperor's feelings, who could accurately guess them? Spending a large amount of time with the ruler is like spending time with a tiger. To us, although he is our father, he is still the ruler first and foremost. Nobody can guess what exactly he is thinking. Even if he constantly dotes on Ming'er, from this day forward… from this day forward, who can say for certain."
"Seventh brother." She tugged at Xuan Tian Hua's sleeve. The strength immediately left her body, as she began to act like a spoiled little girl, "What should I do? Although I did not beat him to death, his state is more or less similar to death…"
Xuan Tian Hua thought a little then said: "There are two paths. One path, you return home. Father Emperor is meeting with some generals today. We can only hope that he does not have time to come and investigate. If it can be delayed until tomorrow when Ming'er has returned, everything will be easier to handle."
Feng Yu Heng shook her head, "Tomorrow… I fear that we cannot delay until tomorrow. What's the other path?"
"The other path is to go into the palace right now with the death waiver that both of you signed and go kneel in front of Heavenly Hall. Da Shun is still waiting for you to produce steel. Father Emperor's punishment, at the very least, will spare your life. If you give him enough face and allow him to easily avoid this situation, it would be better than if you went to hide in your manor."
Upon hearing this, Feng Yu Heng immediately nodded, "This is good. I have never wanted to hide and wait for people to come and save me. Dodging back and forth, it would just be better to stick my head out in case I can see some new hope. That would also be a good return." She suddenly raised her small face with a bright smile. It was as though she was a completely different person from the insane murderous demon from earlier, "Seventh brother, thank you."
"Silly child." He only said this before choking up. "Forget it, do you want me to accompany you?"
Feng Yu Heng shook her head, "No need! I can go on my own. I cannot rely on seventh brother for everything. Moreover, it's very possible that his Majesty will become furious. A-Heng does not want to implicate seventh brother."
Xuan Tian Hua frowned and said: "You know that I am not afraid of being implicated."
"But I am." Feng Yu Heng spoke truthfully, "Once someone is implicated by me, my hands and feet will end up becoming tied up. That's why rather than having an extra person end up becoming an impediment, it would be better to go alone!"
He was still helpless. This girl viewed him as an impediment and a burden? Since when had he, Xuan Tian Hua, reached such a low point? Become disliked by this young girl?
Sighing, he smiled and shook his head, "That's fine. Then go!" He helped her into the carriage then advised her: "If he becomes furious, think of a way to stall for time. You absolutely must wait for Ming'er to return. If things truly do not go well, just send someone to find imperial concubine mother."
"Fine." Feng Yu Heng solemnly nodded, "Don't worry, seventh brother. A-Heng will protect herself."
After she finished speaking, Huang Quan waved her horsewhip, and the carriage rushed in the direction of the imperial palace, leaving the Xiang Palace behind along with Xuan Tian Hua's isolated figure…


text:
"a roots rocker with a powerful voice and a bad-ass Gibson SG that she plays with consummate ease... she could be your new rock 'n' roll hero. Drawing from rock, soul and blues, [Terra Lightfoot] is a monster talent that will be gracing the world's largest festival stages in no time." – PopMatters
With New Mistakes, Canada's Terra Lightfoot offers up something rare: the kind of genuine document that can only come from a road-tested breed of songwriter and performer. Shot through with the guitarist-vocalist's powerful, bluesy soul, vivid lyrics and ferocious six-string virtuosity, it's an unforgettable outing.
From the ground-shaking stomp of "Paradise" and wild-eyed energy of "Pinball King" that open the set to the psychedelic, gospel-tinged album closer "Lonesome Eyes," the steeltown native's third record distills her masterful talent to its electrifying essence.
Produced by Gus van Go and Werner F (Arkells, Sam Roberts Band, Wintersleep), New Mistakes is a heady journey. As poignant as it is rollicking and vulnerable as it is rowdy, it cruises long and sometimes lonesome highways that lead everywhere from brokedown dive bars and endless prairie skies to mountain ranges and the Mojave Desert.
Built around Lightfoot's killer live band, the session impresses on all counts. It's Lightfoot's hungriest and most raw album to date, able to mesmerize with graceful melodies one moment, and step into the ring to deliver a hurricane of hooks or a heart-wrenching chorus the next. Lifted by bright waves of organ and classic roots-rock vibe, "Ruthless" nails that lethal dynamic, slowly building a story of deep connection fraught by distance, until letting loose its knockout crescendo.
Lightfoot's stunning, soulful voice powers her emotional wallops, laid low as a gentle whisper over the swirling finger-picking of "You Get High," or belted out with nuclear swagger over the rock 'n' soul grooves of "Hold You," battling things out with a righteous Jake Clemons sax solo during its climax.
And the only forces that can go toe-to-toe with Lightfoot's vocal prowess are her guitar chops. "Slick Back Kid" is a bluesy scorcher, barreling forward with monster riffs, dappled with hits of slide guitar work from guest vocalist Oliver Wood. "Stars Over Dakota" lays down blistering '70s grooves between feral blasts of overdrive as Lightfoot howls across the American midwest to someone she can't stop thinking about. "Drifter" reflects on love long past, with her emotive guitar playing saying what the lyrics cannot.
That's not to say she's a tentative wordsmith. Lightfoot's evolution into a potent songwriter might be captured best on the poignant "Norma Gale". The tune tells the real life story of its namesake's battle to make it as a songwriter and bass player in the colourful world of '70s country music, fighting to pursue her passion while raising her son alone and touring non-stop. It's easy to hear why Gale's story would resonate with Lightfoot: As tried and true road-dogs, they're kindred spirits, both driven by a creative force they'd be willing to let tear them apart if it had to. And sometimes it does. But, as Lightfoot wails in the song's transcendent finish—though the trek so far has been long and treacherous, and isn't likely to let up—"I knew I had to keep on going." That's how she got here, after all.
It's Lightfoot's relentless commitment to the cause that made this album possible: racking up endless, hard-earned miles, forging and letting go of relationships, and seeking out every sliver of truth in a life on the road that is anything but easy to navigate. It's an odyssey without a map to guide the way, filled with infinite missteps. But if they all sound as wild and beautiful as this, let's hope Terra Lightfoot never stops making New Mistakes.
This project is funded in part by FACTOR, the Government of Canada and Canada's private radio broadcasters. Ce projet est financé en partie par FACTOR, le gouvernement du Canada et les radiodiffuseurs privés du Canada.


text:
Pro users of OS X often feel that the keyboard is the secret weapon to get things done on the desktop. After all, learning the key commands for Finder actions and application menus helps to accelerate many tasks. Over the years, utilities like LaunchBar, Quicksilver, and Butler have provided users with powerful keyboard commands to move around in the Finder, but usually at the expense of alienating new users with steep learning curves. Alfred, on the other hand, lets users harness their keyboard without the barrier of learning complex sets of commands. The free version of the powerful OS X utility is incredibly easy to learn, and the paid version is highly valuable to those who stick with it and want to maximize their usage.
First, let's discuss why using a keyboard is more efficient than a mouse or trackpad—at least for some situations. Human-computer-interaction studies have shown that users can use keyboard commands quickly and with lower error rates in very complex applications that accessed large sets of data. Traditional menus and gestures let users to explore an application to learn it, but once users become familiar with the interface, they may benefit from using keyboard commands as a way to cut down on time (provided they became very familiar with the application). Of course, using keyboard commands well will require a certain level of memorization on the user's part. In other words, if you're thinking of trying out a keyboard utility like Alfred or one of its competitors, you will probably get better results if you commit to using it often.
Andrew and Vero Pepperreli, a husband and wife developer team, created Alfred in 2010 as a way to solve their own problems in OS X workflow. They wanted to access files on the Finder and make web searches really easy, and those needs drove the development of the app. Over time they have expanded the app's scope to serve both novice and expert users. "Both keyboard and touch-based gestures serve their purpose; I've been using a Magic Trackpad for the past few months and absolutely love controlling Spaces and browsing using the trackpad," Vero Pepperrelli told Ars. "That being said, there are certain speedy actions that are best performed with the keyboard, especially as we increase our screen real estate and sometimes have to work out where the mouse is on our huge Apple Display screens."
If you're considering diving into Alfred, the basic, free application will serve as a more than adequate snapshot of its core features. From the moment you start using it, Alfred wants to help you ditch the mouse actions and trackpad gestures that are typically used to move about the Finder. If you are used to using Spotlight to access your apps, files, and other things like contacts, Alfred may provide a nice alternative to do so. You can trigger Alfred using a customizable key command of your liking (such as option-spacebar), and just like with Spotlight, you can quickly view and access the files on your computer. What makes Alfred immediately different from Spotlight is that it appears right in the middle of the screen, with a straightforward UI that begs for attention. The user experience of Aflred brings searches to the center of the user's focus, unlike Spotlight's lurker approach in the corner of the screen.
As far as launchers, go, Alfred isn't breaking a lot of new ground here, or so it seems at first. You can customize what types of results appear in your searches, and Alfred will observe which of those you are accessing most often in order to bring them up higher in its results window. As you can see, its large type face and simple search results makes for a compelling user experience. It works fast and lets you customize the search categories you prefer. By typing file and app names, you will probably save yourself a lot of time to start off with.
Alfred uses the same indexed metadata that Spotlight gathers inside the OS, so running filters in Alfred can also provide with a powerful way to search for files. There's a variety of file types and data you can include or exclude from your queries, including contacts, images, music files, source files, .plist files, and more. Users can also add their own list of file types into Alfred to bring back more accurate results. These finer search filters can also boost your efficiency if you find yourself searching for files on your computer very often.
If having speedy access to the Web is important to you, Alfred lets you query major search engines without using multiple tabs or windows to start each new search. Alfred also indexes your browser bookmarks and makes them accessible via the keyboard. This feature currently only supports Safari bookmarks right now, unfortunately. We also like how Alfred can retrieve results directly from popular websites like Twitter, Wikipedia, Flickr, and Amazon, among others.
Upgrading unlocks the heavy-duty features
Alfred's true secret weapons are found in its array of features aimed at the pro user in the form of its "Power Pack." The company's website provides plenty of information about what's included, but if you downloaded the basic free version via the Mac App Store, you may easily overlook the fact that there's more to the program than just app launching. What's more, if you purchased the app via the Mac App Store and decide that you want to upgrade, you will have to go to the developer's website to re-download and enter the serial number after purchase. (The Alfred team has posted an explanation into the reasons why this is the case—it's basically due to Apple's sandboxing requirement.) The Powerpack is listed for £15.
One of the true time-saving features of Alfred's paid version is its ability to perform actions that are used frequently, like handling files in the Finder. If you are used to opening, renaming, and moving files often, the upgrade will let you do so easily from keyboard. You can use some basic commands like "open" to access specific files, as well as "quit" to close down an application. You can also search inside files, just like in Spotlight. This can be really useful if you often work with text inside documents, but the ability to see file-name results in a larger window at the center of the screen makes Alfred a better choice. Indexing and search results can be refined quite nicely with a large set of filters, so, if you perform very specific searches on your workstation or on the Web, you'll save a lot of time by customizing. Alfred can manipulate files by finding and moving them, and it can even perform some autocompletion for paths. The one thing it can't do is operate on multiple files at once; it can only operate on a single file at a time.
Another versatile feature of Alfred comes how it handles the OS' clipboard and its contents. Have you ever lost a key string of text by moving too quickly through cut-and-paste actions? You can ask Alfred to keep a history of all your clipboard clippings, going back as far as three months. As you copy and paste in applications it will keep those text clippings accessible for easy re-use. If you have privacy concerns, you can ask Alfred to avoid snippets from sensitive applications like 1Password or the Keychain. All the clippings saved in the clipboard can be easily retrieved, and even pasted back into the current application you are using. Best of all, clippings are searchable: in Alfred's paste window, you can begin typing to show you matching clippings. You can also save and append snippets of text as you wish for applications.
Much of Alfred's power comes to life through its extensions, which allow developers to write workflow commands for Alfred to work with popular applications like Twitter and Spotify. AlfredTweet for example, lets you use Alfred to tweet, send direct messages, and more right from the Alfred window. Alfred will let you create and run your own Terminal Shell Scripts, AppleScripts, and workflows easily. Other users have shared their own extensions on the developer's extensions and scripts page.
And there are other small touches that make Alfred a time saver, too. You can use the Calculator app's functions right in the search window by typing your statements, or use the dictionary by simply starting a query with "define." You can also control iTunes playback and even compose emails with the press of a couple of keys. Of course, many Mac keyboards allow you to control iTunes playback already via certain keys, so this feature may not be as useful.
If you're in love with all the customized search filters, settings, and your color themes, you can also sync those across other computers that use Alfred. The app supports iDisk or Dropbox to host this synced data.
As far as looks go, Alfred has a very clean and easy-to-read interface, even if it looks a bit austere. (We suppose that if it's named after a butler, that might be exactly the effect the app's designers were going for.) If you buy the paid version, you can customize Alfred's colors, which is a nice touch. Alfred's interface uses Helvetica for queries for search queries and results, but again, looks are not the most important element here. As an app launcher, it certainly brings user-friendliness to the forefront, and if you are looking to move up a gear or two in your quest for speed, the paid version is certainly worth a try.
- Easy to learn
- Easy implementation of Applescripts, Terminal shell scripts and Automator workflows
- Filtered Spotlight results
- Searchable clipboard history
- Use to play iTunes music
- The app provides usage data to see how often you use it
- No preview or trial period of the power pack to see the extra features
- Downloading pro version means you have to re-download if you used the App Store originally
- Can't manipulate large numbers of files at once


text:
Karachi continues to bleed more and more as a consequence of Pakistan's self-inflicted thousand cuts.
2. At least 27 people have been killed in fresh clashes and targeted attacks since July 23,2011, taking the number of total fatalities this month to 200.Whereas previously, Mohajirs and Pashtuns were killing each other, now Mohajirs have been killing Mohajirs----Mohajir migrants from India's Uttar Pradesh and those from Bihar killing each other.
3.The Mohajirs from Bihar have generally collaborated with Pakistan's Inter-Services Intelligence (ISI). They did so in the pre-1971 East Pakistan and let themselves be used by the ISI and the Jamaat-e-Islami (JEI) for the massacre of the Bengali nationalists, setting in motion the train of events that led to the birth of Bangladesh.
4.When Karachi burst into anti-Government and anti-Sindhi violence in the late 1980s due to the activities of the Mohajir Qaumi Movement (since renamed the Muttahida Qaumi Movement), the ISI sought to drive a wedge between the migrants from Uttat Pradesh, who dominated the leadership and cadre strength of the MQM, and those from Bihar who had grievances against the leadership style of Altaf Hussain, the head of the MQM, whose family had migrated to Pakistan from UP.
5.The ISI encouraged the migrants from Bihar to form their own organisation under the leadership of one Afaq Ahmed called MQM (Haqiqui), the real MQM. The ISI trained and armed the MQM (Haqiqui) to counter the MQM of Altaf.
6. When Gen. Pervez Musharraf, a Mohajir from Delhi, came to power he made peace with Altaf's MQM by stopping the ISI's support to MQM (Haqiqui).
7. Recent reports indicate that concerned with growing violence in Karachi, the ISI has reverted to its old policy of using migrants from Bihar to counter Altaf's MQM. The leaders and cadres of MQM (Haqiqui) arrested and jailed when Musharraf was in power, are being released and encouraged to counter the activities of Altaf's organisation.
8. This has led to a recrudescence of violent clashes between the migrants from Uttar Pradesh and those from Bihar---thereby further complicating an already complicated situation in Karachi.
9. This may please be read in continuation of my earlier article of July 9,2011, titled KARACHI, BEIRUT OF SOUTH ASIA at http://www.southasiaanalysis.org/papers46/paper4594.html
( The writer is Additional Secretary (retd), Cabinet Secretariat, Govt. of India, New Delhi, and, presently, Director, Institute For Topical Studies, Chennai, and Associate of the Chennai Centre For China Studies. E-mail: email@example.com .Twitter: @SORBONNE75 )
Monday, July 25, 2011
Subscribe to: Posts (Atom)


text:
CMMG intended to make the magazine extensions stackable - unfortunately what they produced doesn't actually stack. Personally - 30 is nice, but I'd rather have two 20s than a 40.Augustus wrote:Hmmmm.... If one were to say... Buy ten CMMG extensions... Could one theoretically make a huge magazine that holds something like 100 rounds by training all of the extensions together, or do the extensions have a built in baseplate that would prevent this? (Of course you would need a huge spring to do this...)
archive/index.php_t-1830.html" onclick="window.open(this.href);return false;


text:
Department of Health and Human Services
Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov)
Components of Participating Organizations
National Center for Research Resources (NCRR), (http://www.ncrr.nih.gov)
Title: Clinical and Translational Science Coordinating Center (U54)
Announcement Type
Update: The following update relating to this announcement has been issued:
Key Dates
Release Date: July 16, 2010
Letters of Intent Receipt Date: December 15, 2010
Application Receipt Date: January 12, 2011
Peer Review Date: June 2011
Council Review Date: September 2011
Earliest Anticipated Start Date: December 2011
Additional Information To Be Available Date (Url Activation Date): Not Applicable
Expiration Date: January 13, 2011
Due Dates
for E.O. 12372
Not Applicable
Additional Overview Content
Executive Summary
Table of Contents
I Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt, Review and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application to the NIH
C. Application Processing
D. Application Assignment
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review Information
1. Criteria
2. Review and Selection Process
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
A. Cooperative Agreement Terms and Conditions of Award
1. Principal Investigator Rights and Responsibilities
2. NIH Responsibilities
3. Collaborative Responsibilities
4. Dispute Resolution Process
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
Section VIII. Other Information - Required Federal Citations
Part II - Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The purpose of this FOA is to solicit applications for a Clinical and Translational Science Coordinating Center (CTSCC). The CTSCC will encourage and facilitate sharing and interactions within the CTSA Consortium and of the Consortium with non-CTSA institutions, organizations, and programs also focused on advancing the efficiency and quality of clinical and translational research and training. The CTSCC will also facilitate communication of CTSA Consortium activities to others. The CTSCC will provide a web-based site for collaboration, including wikis, forums, and public and private work spaces, to facilitate the communal development and adoption of best practices for conduct of clinical and translational research to enhance quality, efficiency, and value. This Center will also support conference calls and face to face meetings of the CTSA Consortium committees and working groups. In addition, the CTSCC will provide and manage the public non-government website of the Clinical and Translational Science Consortium to communicate the activities, resources, and best practices of the CTSA Consortium and individual CTSAs across the country to the public, industry, and basic, clinical and translational science investigators and students. The CTSCC will not provide resources for conduct of research or research projects. This center will facilitate collaboration and communication within the CTSA Consortium and with non-CTSA organizations, including industry, to advance clinical and translational research and training generally and to advance development, sharing, and adoption of best practices in clinical and translational research, training, and outreach.
Background: The Clinical and Translational Science Award (CTSA) program provides grants to institutions to create an integrated academic home to train multi- and inter-disciplinary investigators, award advanced degrees in clinical and translational science, and provide investigators and research teams with research cores, tools, and a local environment that encourages and facilitates the conduct of clinical and translational research, including with community and industry partners. As cooperative agreement grants, each awardee is also required to participate in the CTSA Consortium, whose goal is to reduce the barriers and increase efficiency of multi-institutional clinical and translational research both within the Consortium and with other partners, to share knowledge and disseminate best practices for clinical and translational research widely, and to collaborate together and with others to enhance the national environment for clinical and translational research. The NCRR expects the CTSA Consortium to include 60 CTSA awards (excluding the Coordinating Center). The CTSA Consortium Steering Committee, the core governing and decision making body of the CTSA Consortium, is composed of the PI of each CTSA and trans-NIH representatives. In addition, there are over 20 major committees, each of which may include a number of working groups. Committees, focused on key functions of CTSAs such as Community Engagement, Regulatory Knowledge, Translational Research, Biomedical Informatics, allow individuals from CTSAs to share best practices, information, and work on shared projects. Other committees address specific areas of interest, including advancing pediatric clinical and translational research. Each Committee generally includes a representative from each of the CTSAs, while working groups are generally smaller. For further information on the CTSA Consortium, see www.ctsaweb.org.
Specific Objectives: The goal of the CTSCC is to provide staff and resources to support the national CTSA Consortium in its activities. Specific objectives include, but are not limited to:
Special Requirements:
It is anticipated that the CTSCC will establish an independent External Advisory Committee (EAC) that would annually review the activities, progress, and effectiveness of the CTSCC and provide recommendations to the Principal Investigator. It is expected that this EAC would include individuals who have experience in managing large coordinating centers, representatives from the various communities served by the CTSCC, and experts in facilitating national collaboration and communication. The application should include a description of the types of individuals but should not name any potential members and no members should be contacted prior to review of the application.
As noted in the Section VI.2.A Cooperative Agreement Terms and Conditions of Award, the PI of the CTSCC will participate in the CTSA Consortium Steering Committee as a voting member, and provide updates on current activities and discuss proposed modifications to CTSCC activities and support with the CCSC on at least a quarterly basis.
The application should address how the proposed management of each specific objective would facilitate the transition of those activities to a potential successor at the end of the five-year project period. This should include ongoing documentation of required software, hardware, and licenses, as well as ongoing maintenance of standard operating procedures, best practices, and other documentation for management of the CTSCC. Inclusion of approaches and activities that would facilitate the transition of the activities and infrastructure of the CTSC, including content of the public website and collaboration site, at the end of the award period is required.
The applicant must include funds for the PI and key personnel to attend the annual two-day CTSA Consortium Steering Committee meeting in the Bethesda area.
See Section VIII, Other Information - Required Federal
Citations, for policies related to this announcement.
Section II. Award Information
1. Mechanism of Support
This funding opportunity will use the U54 award mechanism(s).
The Project Director/Principal Investigator (PD/PI) will be solely responsible for planning, directing, and executing the proposed project.
This FOA uses "Just-in-Time" information concepts. It also uses non-modular budget formats described in the PHS 398 application instructions (see https://grants.nih.gov/grants/funding/phs398/phs398.html).
This funding opportunity will use a cooperative agreement award mechanism. In the cooperative agreement mechanism, the Project Director/Principal Investigator (PD/PI) retains the primary responsibility and dominant role for planning, directing, and executing the proposed project, with NIH staff being substantially involved as a partner with the Principal Investigator, as described under the Section VI. 2. Administrative Requirements, "Cooperative Agreement Terms and Conditions of Award". It is unknown at this time if this program will be reissued.
2. Funds Available
Future year amounts will depend on annual appropriations.
Because the nature
and scope of the proposed activities may vary from application to application,
it is anticipated that the size and duration of each award may also vary.
Although the financial plans of the NCRR provides support for this program,
awards pursuant to this funding opportunity are contingent upon the
availability of funds and the receipt of a sufficient number of meritorious
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Section III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
The following organizations/institutions are eligible to apply:
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH program support.
2. Cost Sharing or Matching
This program does not require cost sharing as defined in the current NIH Grants Policy Statement.
3. Other-Special Eligibility Criteria
Number of Applications. Applicants may submit one application.
Resubmissions. Resubmission applications are not permitted in response to this FOA.
Renewals. Renewal applications are not permitted in response to this FOA.
Section IV. Application and Submission Information
1. Address to
Request Application Information
The current PHS 398 application instructions are available at https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: email@example.com.
Telecommunications for the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Prepare all applications using the PHS 398 application forms and in accordance with the PHS 398 Application Guide (https://grants.nih.gov/grants/funding/phs398/phs398.html).
must have a D&B Data Universal Numbering System (DUNS) number as the
universal identifier when applying for Federal grants or cooperative
agreements. The D&B number can be obtained by calling (866) 705-5711 or
through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of the face page of the PHS 398
The title and number of this funding opportunity must be typed in item (box) 2 only of the face page of the application form and the YES box must be checked.
Additional information is available in the PHS 398 grant application instructions.
Submission Dates and Times
Applications must be received on or before the receipt date described below (Section IV.3.A). Submission times N/A.
3.A. Receipt, Review and Anticipated Start Dates
of Intent Receipt Date: December
15, 2010
Application Receipt Date: January 12, 2011
Peer Review Date: June 2011
Council Review Date: September 2011
Earliest Anticipated Start Date: December 2011
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent that includes the following information:
Although a letter of
intent is not required, is not binding, and does not enter into the review of a
subsequent application, the information that it contains allows NCRR staff to
estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed in Section IV.3.A.
The letter of intent should be sent to:
Office of Review
National Center for Research Resources
6701 Democracy Boulevard
Building Number, Room Number 1084
Bethesda, MD 20892-4874
Bethesda, MD 20817 (FedEX or courier)
Email: firstname.lastname@example.com
3.B. Sending an Application to the NIH
Applications must be prepared using the forms found in the PHS 398 instructions for preparing a research grant application. Submit a signed, typewritten original of the application, including the checklist, and three signed photocopies in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
Personal deliveries of applications are no longer
permitted (see https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-040.html).
At the time of submission, two additional copies of the application must be sent to:
Office of Review
National Center for Research Resources
6701 Democracy Boulevard, Room 1001
Bethesda, MD 20892-4874 (Regular Mail)
Bethesda, MD 20817 (FedEX or courier)
Telephone: (301) 435-0811
3.C. Application Processing
Applications must be received on or before the application receipt date described above (Section IV.3.A.). If an application is received after that date, the application may be delayed in the review process or not reviewed. Upon receipt, applications will be evaluated for completeness by the CSR and for responsiveness by the reviewing Center. Incomplete and/or non-responsive applications will not be reviewed.
The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. However, when a previously unfunded application, originally submitted as an investigator-initiated application, is to be submitted in response to a funding opportunity, it is to be prepared as a NEW application. That is, the application for the funding opportunity must not include an Introduction describing the changes and improvements made, and the text must not be marked to indicate the changes from the previous unfunded version of the application.
Information on the status of an application should be checked by the Principal Investigator in the eRA Commons at: https://commons.era.nih.gov/commons/.
4. Intergovernmental Review
This initiative is not subject to intergovernmental
5. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The Grants Policy Statement can be found at NIH Grants Policy Statement.
Pre-award costs are allowable. A grantee may, at its own risk and without NIH prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award if such costs: 1) are necessary to conduct the project, and 2) would be allowable under the grant, if awarded, without NIH prior approval. If specific expenditures would otherwise require prior approval, the grantee must obtain NIH approval before incurring the cost. NIH prior approval is required for any costs to be incurred more than 90 days before the beginning date of the initial budget period of a new award.
The incurrence of pre-award costs in anticipation of a competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred. NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project (see NIH Grants Policy Statement https://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part6.htm.)
6. Other Submission Requirements
Special Requirements that must be addressed in the application.
The applicant must include funds for the PI and key personnel to attend the annual two-day CTSA Consortium Steering Committee meeting in the Bethesda area.
The application should address how the proposed management of each specific objective would facilitate the transition of those activities to a potential successor at the end of the five-year project period. This should include ongoing documentation of required software, hardware, and licenses, as well as ongoing maintenance of standard operating procedures, best practices, and other documentation for management of the CTSCC. Inclusion of approaches and activities that would facilitate the transition of the activities and infrastructure of the CTSCC, including content of the public website and collaboration site, at the end of the award period is required.
It is anticipated that the CTSCC will establish an independent External Advisory Committee (EAC) that would annually review the activities, progress, and effectiveness of the CTSCC and provide recommendations to the Principal Investigator. It is expected that this EAC would include individuals who have experience in managing large coordinating centers, representatives from the various communities served by the CTSCC, and experts in facilitating national collaboration and communication. The application should include a description of the types of individuals but should not name any potential members and no members should be contacted prior to review of the application.
As noted in the Section VI.2.A Cooperative Agreement Terms and Conditions of Award, the PI of the CTSCC will be a voting member of the CTSA Consortium Steering Committee, and provide updates on current activities and discuss proposed modifications to CTSCC activities and support with the CCSC on at least a quarterly basis.
Cooperative agreements: Awardees must agree to the "Cooperative Agreement Terms and Conditions of Award" in Section VI.2.A "Award Administration Information".
Organization of the Application: The Research Strategy section should be organized to address the specific objectives of this funding opportunity: coordination and administrative support; enabling collaboration; and communication, including management of a public website. The Research Strategy section should total 30 pages or less and include separate sections for each of the above objectives.
PHS398 Research Plan Sections
All application instructions outlined in the PHS398 Application Instructions are to be followed, with the following additional requirements:
This FOA uses non-modular budget formats described in the PHS 398 application instructions (see https://grants.nih.gov/grants/funding/phs398/phs398.html).
Appendix Materials
No Appendix Materials are allowed.
NIH considers the sharing of unique research resources developed through NIH-sponsored research an important means to enhance the value of, and advance research. When resources have been developed with NIH funds and the associated research findings published or provided to NIH, it is important that they be made readily available for research purposes to qualified individuals within the scientific community. If the final data/resources are not amenable to sharing, this must be explained in Resource Sharing section of the application. See https://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm.
(a) Data Sharing Plan: Regardless of the amount requested, applicants are expected to include a brief 1-paragraph description of how final data will be shared, or explain why data-sharing is not possible. Applicants are encouraged to discuss data-sharing plans with their NIH program contact. See Data-Sharing Policy or https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html.
(b) Plan for Sharing Software: A software dissemination plan, with appropriate timelines, is expected to be included in the application. There is no prescribed single license for software produced in this project, however reviewers will be asked to comment on the dissemination plan based on its likely impact. A dissemination plan guided by the following principles is thought to promote the largest impact:
1. The software should be freely available to biomedical researchers and educators in the non-profit sector, such as institutions of education, research institutions, and government laboratories.
2. The terms of software availability should include the ability of researchers outside the Center to modify the source code and to share modifications with other colleagues as well as with the Center. The terms should also permit the dissemination and commercialization of enhanced or customized versions of the software, or incorporation of the software or pieces of it into other software packages.
3. To preserve utility to the community, the software should be transferable such that another individual or team can continue development in the event that the original investigators are unwilling or unable to do so.
The application is expected to include written statements from the officials responsible for intellectual property issues at all of the applicant institutions (including sub-contractors) to the effect that the institution supports and agrees to abide by the software dissemination plans put forth in the application. These letters should be clear expressions of commitment consistent with achieving the goals of the program. A separate letter should be included from each institution or organization, including each subcontractor.
The initial review group will comment on the appropriateness of the proposed plan for data sharing and the proposed plan for software sharing. These comments will be factored into the overall score of the application. Program staff and advisors will also consider the adequacy of the dissemination plans as one of the criteria for award. The proposed sharing plans, after negotiation with the applicant when necessary, will be made a condition of the award. Evaluation of annual non-competing progress reports will include assessment of the responsiveness to NIH guidelines of data, materials, methods, and software dissemination practice by the grantee.
The following resource sharing policies do not apply to this FOA:
Section V. Application Review Information
1. Criteria
Only the review criteria described below will be considered in the review process.
2. Review and Selection Process
Review Process
Applications that are complete and responsive to the FOA will be evaluated for scientific and technical merit by an appropriate peer review group convened by NCRR and in accordance with NIH peer review procedures (http://grants1.nih.gov/grants/peer/), using the review criteria stated below.
As part of the scientific peer review, all applications will:
The mission of the NIH is to support science in pursuit of knowledge about the biology and behavior of living systems and to apply that knowledge to extend healthy life and reduce the burdens of illness and disability. As part of this mission, applications submitted to the NIH for grants or cooperative agreements to support biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Overall Impact
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following five scored review criteria, and additional review criteria (as applicable for the project proposed).
Scored Review Criteria
Reviewers will consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance. Will the proposed Clinical and Translational Science Coordinating Center facilitate the coordination, sharing, collaboration, and communication among the CTSAs in the national CTSA Consortium? Will the proposed Clinical and Translational Science Coordinating Center facilitate the coordination, sharing, collaboration, and communication among the national CTSA Consortium and a broad range of non-CTSA institutions, organizations, and programs? How will the proposed Clinical and Translational Science Coordinating Center advance the field of clinical and translational science?
Investigator(s). Are the PI, collaborators, and other personnel well suited to the project? Have they demonstrated ongoing records of accomplishments in support of coordination, collaboration, and communication of large national-level consortia or networks? Do the personnel have complementary and integrated expertise? Are the proposed staffing approach, governance and organizational structure appropriate for the project?
Innovation. Does the application challenge and seek to impact national interaction, collaboration, and communication paradigms by utilizing novel approaches, methodologies, or tools? Does the application include mechanisms for leveraging novel collaboration and communication strategies? Does the application indicate creativity and flexibility to innovate on an on-going basis while meeting the objectives of the solicitation?
Approach. Are the overall strategy, approach, and implementation well-reasoned and appropriate to accomplish the specific objectives of the project? Are potential problems, alternative strategies, and benchmarks for success presented? Will the proposed approach allow rapid deployment and management of a CTSA Consortium public non-government website? Will the proposed approach allow rapid deployment and use of collaborative tools by the consortium members, committees, and partners? Are the proposed activities to enhance coordination, collaboration, and communication flexible enough to meet evolving needs of the CTSA consortium and potential new partnerships with non-CTSA groups? Is the plan for administrative support for the CTSA committee synergistic with proposed coordination and collaboration activities? Is the proposed External Advisory Committee constituted to provide independent, thoughtful, creative, and practical recommendations to address challenges and improve performance? Will the proposed approach and documentation facilitate transition of the content and activities of the coordinating center to a successor at the end of the project period?
Environment. Does the environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available and adequate to ensure a rapid start and continuing evolution of the proposed support center? Will the project benefit from unique features of the institutional environment, workforce, or collaborative arrangements?
Additional Review Criteria
As applicable for the project proposed, reviewers will consider the following additional items in the determination of overall scientific and technical merit, but will not give separate scores for these items.
Data Sharing Plan. A data sharing plan is expected to be included in the application as outlined in the Other Submission Requirements section. The reviewers will comment on the appropriateness and adequacy of the proposed data sharing plan and factor their review into the determination of the overall score.
Plan for Sharing Software. A software dissemination plan, with appropriate timelines, is expected to be included in the application as outlined in the Other Submission Requirements section. Reviewers will comment on and factor into their overall score the appropriateness and adequacy of the proposed plan for software sharing. The review should be guided by the following principles thought likely to promote the largest impact:
1. The software should be freely available to biomedical researchers and educators in the non-profit sector, such as institutions of education, research institutions, and government laboratories.
2. The terms of software availability should include the ability of researchers outside the Center to modify the source code and to share modifications with other colleagues as well as with the Center. The terms should also permit the dissemination and commercialization of enhanced or customized versions of the software, or incorporation of the software or pieces of it into other software packages.
3. To preserve utility to the community, the software should be transferable such that another individual or team can continue development in the event that the original investigators are unwilling or unable to do so.
Protections for Human Subjects. For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials.
Inclusion of Women, Minorities, and Children. When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children.
Vertebrate Animals. The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information, see https://grants.nih.gov/grants/olaw/VASchecklist.pdf.
Biohazards. Not applicable to this FOA.
Resubmission Applications. Resubmissions are not allowed for this FOA.
Renewal Applications. Renewals are not allowed for this FOA.
Revision Applications. Revisions are not allowed for this FOA.
Additional Review Considerations
As applicable for the project proposed, reviewers will address each of the following items, but will not give scores for these items and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations. Foreign are not allowed for this FOA.
Select Agents Research. Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Budget and Period Support. Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
The following resource sharing policies do not apply to this FOA:
Selection Process
The following will be considered in making funding decisions:
NIH considers the following in evaluating Center grant applications:
3. Anticipated Announcement and Award
Not Applicable
Section VI. Award Administration Information
1. Award Notices
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
If the application is under consideration for funding,
NIH will request "just-in-time" information from the applicant. For
details, applicants may refer to the NIH
Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards,
Subpart A: General.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official.
Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See Also Section IV.5. Funding Restrictions.
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (https://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm) and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities (https://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).
The following Terms and Conditions will be incorporated into the award statement and will be provided to the Principal Investigator as well as to the appropriate institutional official, at the time of award.
2.A. Cooperative Agreement Terms
and Conditions of Award
The following special terms of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines, HHS grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
2. A.1. Principal Investigator Rights and Responsibilities
The Principal Investigator will have the primary responsibility for the overall function of the Clinical and Translational Science Coordinating Center. This includes responsibility for the coordination and administrative support of the CTSA Consortium committees and working groups, enabling collaboration within the CTSA Consortium and with others to facilitate communal development and adoption of best practices, and communication and outreach of the CTSA Consortium, including management of a non-government website for the CTSA Consortium.
The Principal Investigator is expected to participate in all meetings of the CTSA Consortium Steering Committee as a voting member. In addition, the CTSCC PI will present at least quarterly reports to the CTSA Steering Committee of the current and planned activities of the CTSCC. In addition, the PI will serve as an ad hoc member of the CTSA Consortium Executive Committee and is expected to participate in all meetings.
All software developed in this project must be made available as outlined in the Special Requirements.
An NIH Project Coordinator will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below.
The NIH Project Coordinator will serve as a voting member of the CTSA Steering Committee and participate in other committees as appropriate. The NIH Project Coordinator will facilitate interactions with other NCRR and NIH programs; provide relevant expertise and overall knowledge of NIH-sponsored programs and other projects to facilitate collaboration, and provide input and suggestions when challenges or opportunities arise. The NIH Project Coordinator will ensure the CTSCC can connect with a wide range of other projects and programs relevant to clinical and translational science. However, the dominant role and prime responsibility for the project resides with the awardee.
Additionally, an NCRR Program Officer will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. This individual is responsible for coordinating the assessment of the progress.
2.A.3. Collaborative Responsibilities
The Principal Investigator and NIH Project Coordinator will serve as voting members of the CTSA Consortium Steering Committee (CCSC); however, neither may serve as a co-Chair of the CCSC. The Principal Investigator will also serve as an ad-hoc member of the CTSA Consortium Executive Committee (CCEC) to ensure open communication between the leadership of the CTSA Consortium and the CTSCC.
The national CTSA Consortium Steering Committee shall
be a forum for sharing policies, practices, and resources and for discussion of
opportunities, impediments, joint agreement on broad issues impeding clinical
research, government policies and practices, and other appropriate topics. The
Committee will identify and approve best practices and policies that will
advance clinical and translational research as a discipline and facilitate
collaboration and sharing among CTSA institutions and with partners in clinical
and translational research, e.g., industry, laboratories, hospitals. Awardee members of the Steering Committee, including
the CTSCC, will be required to accept and implement policies approved by the
Steering Committee.
2.A.4. Dispute Resolution Process
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulations 42 CFR Part 50, Subpart D and HHS regulations 45 CFR Part 16.
3. Reporting
The awardee will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement. This Non-Competing Continuation Grant Progress Report (PHS2590) may be required to follow Special Instructions from NCRR for Center-like programs.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated.
encourage your inquiries concerning this funding opportunity and welcome the
opportunity to answer questions from potential applicants. Inquiries may fall
into three areas: scientific/research, peer review, and financial or grants
management issues:
1. Scientific/Research Contacts:
Renee Joskow, DDS, MPH
Division for Clinical Research Resources
National Center for Research Resources
6701 Democracy Boulevard, Room 923
Bethesda, MD 20892-4874
Telephone: (301) 435-0961
Email: firstname.lastname@example.com
Collier, MD
Office of the Director
National Center for Research Resources
Democracy One, Room 998
6701 Democracy Boulevard Avenue
Bethesda, MD 20892
Telephone: (301) 435-0794
Email: email@example.com
2. Peer Review Contacts:
Dr. Mohan Viswanathan
Office of Review
National Center for Research Resources
6701 Democracy Blvd
Democracy 1, Room Number 1084
Bethesda, MD 20892
Telephone: (301) 435-0829
Email: firstname.lastname@example.com
3. Financial or Grants Management Contacts:
Vicki Maurer
Office of Grants Management
National Center for Research Resources
6701 Democracy Boulevard, Room 1042
Bethesda, MD 20892-4874
Telephone: (301) 435-0837
Email: firstname.lastname@example.com
Section VIII. Other Information
Required Federal Citations
Use of Animals in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (https://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (https://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, https://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (https://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their institutions, on issues related to institutional policies and local IRB rules, as well as local, State and Federal laws and regulations, including the Privacy Rule.
for Genome-Wide Association Studies (GWAS):
NIH is interested in advancing genome-wide association studies (GWAS) to identify common genetic factors that influence health and disease through a centralized GWAS data repository. For the purposes of this policy, a genome-wide association study is defined as any study of genetic variation across the entire human genome that is designed to identify genetic associations with observable traits (such as blood pressure or weight), or the presence or absence of a disease or condition. All applications, regardless of the amount requested, proposing a genome-wide association study are expected to provide a plan for submission of GWAS data to the NIH-designated GWAS data repository, or provide an appropriate explanation why submission to the repository is not possible. Data repository management (submission and access) is governed by the Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies, NIH Guide NOT-OD-07-088. For additional information, see https://grants.nih.gov/grants/gwas/.
to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this funding opportunity in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.
Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see https://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh Dole Act (see the NIH Grants Policy Statement https://grants.nih.gov/grants/policy/nihgps_2003/index.htm). All investigators submitting an NIH application or contract proposal, beginning with the October 1, 2004 receipt date, are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.
Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.
All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (https://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-116.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research.
NIH Public Access
Policy Requirement:
In accordance with the NIH Public Access Policy (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-033.html) investigators must submit or have submitted for them their final, peer-reviewed manuscripts that arise from NIH funds and are accepted for publication as of April 7, 2008 to PubMed Central (http://www.pubmedcentral.nih.gov/), to be made publicly available no later than 12 months after publication. As of May 27, 2008, investigators must include the PubMed Central reference number when citing an article in NIH applications, proposals, and progress reports that fall under the policy, and was authored or co-authored by the investigator or arose from the investigator's NIH award. For more information, see the Public Access webpage at http://publicaccess.nih.gov/.
for Privacy of Individually Identifiable Health Information:
The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule", on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. For publications listed in the appendix and/or Progress report, internet addresses (URLs) must be used for publicly accessible on-line journal articles. Unless otherwise specified in this solicitation, Internet addresses (URLs) should not be used to provide any other information necessary for the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site.
People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This FOA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at https://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50% of their time (at least 20 hours per week based on a 40 hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health®
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
"UFOs over cyprus"?
Posted by dandare on February 18, 2008
In a recent feature article, written by Jean Christou (at cyprus-mail.com) entitled "UFOs over Cyprus?" it mentions :
"THEY never seem to show up on civil aviation or military radar, and Cypriot pilots say they have not seen any.
Yet Cyprus appears to be a hotbed of UFO activity given the number of sightings reported by members of the public.
The latest incident was some two weeks ago over Pervolia near Larnaca, which happens to be near the airport and close enough to the British base of Dhekelia" (extract from article).
It then goes on to recount other sightings too… not sure of the accuracy, and it seems to like to quote from UFO monthly magazine (that was, was known to over do articles/facts). Worth a blog entry though.
I do not know much about UFO sightings in Cyprus, to be honest.


text:
- Free delivery and returns
- Credit card payment
- Lead time:7 days
5 year warranty
30 day return policy
Purchase on invoice
Payment after delivery
Product description
An icon of modernism, the Barcelona chair's design was inspired by the campaign and folding chairs of ancient times. Created by Ludwig Mies van der Rohe for the German Pavilion at the 1929 Barcelona Exposition, the Barcelona chair features the pure compositional structure that now epitomizes Modern architecture and is a chic requirement of the designer interiors. This high quality reproduction is manufactured to almost exact specifications. Whether your home has modern furniture, retro furniture or contemporary furniture - the Barcelona chair will blend in perfectly to suit any ambiance or decor. The epitome of style and trend as a modern day furniture with a smooth blend in the themed furniture always stands out with the Barcelona effect. The Barcelona chair upholstered with Premium Quality Aniline Leather. moDecor does not hold any affiliation with any other party who may sell, produce, reproduce or distribute modern-classic furniture or other similar products. All products made for and on behalf of moDecor are quality reproductions.


text:
SUPERSEDED (click for Active standard)
Active (view current version of standard)
1. Scope
1.1 This specification covers minimum requirements for steel fibers intended for use in fiber-reinforced concrete. Five types of steel fibers for this purpose are defined as pieces of smooth or deformed cold-drawn wire; smooth or deformed cut sheet; melt-extracted fibers; mill-cut or modified cold-drawn wire steel fibers that are sufficiently small to be dispersed at random in a concrete mixture.
1.2 This specification provides for measurement of dimensions, tolerances from specified dimensions, and required minimum physical properties, and prescribes testing procedures to establish conformance to these requirements.
1.3 In the case of conflict between a requirement of a product specification and a requirement of this specification, the product specification shall prevail. In the case of a conflict between a requirement of the product specification or a requirement of this specification and a more stringent requirement of the purchase order, the purchase order shall prevail. The purchase order requirements shall not take precedence if they, in any way, violate the requirements of the product specification or this specification; for example, by the waiving of a test requirement or by making a test requirement less stringent.
1.4 The values stated in either SI units or inch-pound units are to be regarded separately as the standard. Within the text, the inch-pound units are shown in brackets. The values stated in each system may not be exact equivalents; therefore, each system shall be used independently of the other. Combining values from the two systems may result in non-conformance with the standard.
2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard.
ASTM Standards
A370 Test Methods and Definitions for Mechanical Testing of Steel Products
A700 Guide for Packaging, Marking, and Loading Methods for Steel Products for Shipment
C1116/C1116M Specification for Fiber-Reinforced Concrete
ACI DocumentsACI 506.1 Guide to Fiber-Reinforced Shotcrete ACI 544.1R Committee Report on Fiber-Reinforced Concrete
U.S. Federal StandardsFed. Std. No. 123 Marking for Shipment (Civil Agencies)
U.S. Military StandardsMIL-STD-129 Marking for Shipment and Storage
ICS Code
ICS Number Code 77.140.15 (Steels for reinforcement of concrete)
|Link Here
|Link to Active (This link will always route to the current Active version of the standard.)
Citation Format
ASTM A820 / A820M-06, Standard Specification for Steel Fibers for Fiber-Reinforced Concrete, ASTM International, West Conshohocken, PA, 2006, www.astm.orgBack to Top


text:
There will be many more exciting gadgets launched this week, but few that sell as widely (or as well priced, we guess) as Canon's new standard definition camcorders.
Four Flash memory shooters to warm up with. All four have Canon's unique Video Snapshot function to automatically grab short movie clips at the touch of a button.
These clips are the supposedly the perfect size for playing back in sequence, in-camera or uploading to YouTube later on.
They also have a new Pre REC function where, as soon as the record button is pushed, the preceding three seconds of action are also captured. Plus, they have a dedicated Playback button to aid viewing.
Huge lens
All have zooms over 40x (!) and a quick charge function that gives up to one hour's shooting from just a 20 minute charge. From fully charged, they can manage a very healthy 3.5 hours' shooting.
The Legria FS22 has 32GB of memory, the Legria FS21, 16GB, and the Legria FS20, 8GB built in. The Legria FS200 records direct to SD/SDHC cards.
The other two camcorders released today don't have a fancy, schmany new brand name. The DC420 has 45x zoom, the DC410 41x, record video to DVD and stills to an SD card slot.
Prices and pics to follow!